BioCentriq, Inc., a global cell therapy Contract Development and Manufacturing Organization (CDMO), has enhanced its partnership with Pluristyx Inc., an early stage, privately held biotechnology company specializing in Induced Pluripotent Stem Cell (iPSC) products.   Through BioCentriq’s process development services, their strategic collaboration now includes seamless access to Pluristyx’s proprietary iPSC lines to help lower the barrier to entry, provide a swift translation to clinic, a...